Arrowhead Regains Full Rights to ARO-PNPLA3 After Janssen Terminates Collaboration

ARROWHEAD PHARMACEUTICALS, INC.

Janssen terminated the Research Collaboration and Option Agreement with Arrowhead effective April 7, 2023.
Arrowhead regains all rights and licenses to ARO-PNPLA3 (formerly JNJ-75220795), a NASH candidate.
Phase 1 data showed up to 40% mean reduction in liver fat in PNPLA3 I148M homozygotes after a single dose.
No serious adverse events reported; safety profile encouraging with mostly mild AEs.
Arrowhead plans to design a Phase 2 study and assess options for communicating full Phase 1 results.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. terminated Collaboration Agreement with Janssen Pharmaceuticals, Inc. (effective 2023-04-07).

Action: termination
Agreement: collaboration
Counterparty: Janssen Pharmaceuticals, Inc.
Effective: 2023-04-07

Exact text from the filing

On February 10, 2023, Arrowhead Pharmaceuticals, Inc. (the “Company”) received notice from Janssen Pharmaceuticals, Inc. (“Janssen”) that Janssen has elected to terminate the Research Collaboration and Option Agreement between the Company and Janssen, dated October 3, 2018 (as amended by Amendment No. 1 to the Research Collaboration and Option Agreement between the Company and Janssen, dated as of November 14, 2019, the “Collaboration Agreement”).

View on SEC.gov

Browse all material agreements →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-003635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.